PL2349341T3 - Pegylacja rekombinowanych czynników krzepnięcia krwi w obecności przeciwciał zwierzęcych - Google Patents

Pegylacja rekombinowanych czynników krzepnięcia krwi w obecności przeciwciał zwierzęcych

Info

Publication number
PL2349341T3
PL2349341T3 PL09748174T PL09748174T PL2349341T3 PL 2349341 T3 PL2349341 T3 PL 2349341T3 PL 09748174 T PL09748174 T PL 09748174T PL 09748174 T PL09748174 T PL 09748174T PL 2349341 T3 PL2349341 T3 PL 2349341T3
Authority
PL
Poland
Prior art keywords
pegylation
blood coagulation
coagulation factors
bound antibodies
recombinant blood
Prior art date
Application number
PL09748174T
Other languages
English (en)
Inventor
Artur Mitterer
Michael Graninger
Meinhard Hasslacher
Original Assignee
Baxalta Inc
Baxalta GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta Inc, Baxalta GmbH filed Critical Baxalta Inc
Publication of PL2349341T3 publication Critical patent/PL2349341T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PL09748174T 2008-10-15 2009-10-14 Pegylacja rekombinowanych czynników krzepnięcia krwi w obecności przeciwciał zwierzęcych PL2349341T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10554808P 2008-10-15 2008-10-15
EP09748174.1A EP2349341B1 (en) 2008-10-15 2009-10-14 Pegylation of recombinant blood coagulation factors in the presence of bound antibodies
PCT/US2009/060633 WO2010045321A2 (en) 2008-10-15 2009-10-14 Pegylation of recombinant blood coagulation factors in the presence of bound antibodies

Publications (1)

Publication Number Publication Date
PL2349341T3 true PL2349341T3 (pl) 2014-03-31

Family

ID=42035746

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09748174T PL2349341T3 (pl) 2008-10-15 2009-10-14 Pegylacja rekombinowanych czynników krzepnięcia krwi w obecności przeciwciał zwierzęcych

Country Status (9)

Country Link
US (1) US8143347B2 (pl)
EP (1) EP2349341B1 (pl)
JP (1) JP4966434B2 (pl)
AU (1) AU2009303368B2 (pl)
CA (1) CA2738064C (pl)
DK (1) DK2349341T3 (pl)
ES (1) ES2441941T3 (pl)
PL (1) PL2349341T3 (pl)
WO (1) WO2010045321A2 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
GB2516388A (en) * 2012-04-16 2015-01-21 Cantab Biopharmaceuticals Patents Ltd Optimised subcutaneous therapeutic agents
CN102776260B (zh) * 2012-07-26 2015-04-29 上海泰龙生物医药科技有限公司 一种高效表达重组人凝血八因子的方法
KR20150133576A (ko) 2014-05-20 2015-11-30 삼성전자주식회사 화학적 개질된 표적화 단백질 및 그의 이용
CN105237762B (zh) * 2015-10-27 2017-11-14 深圳市健元医药科技有限公司 Peg化亮丙瑞林
PE20191347A1 (es) 2017-02-01 2019-09-30 Novo Nordisk As Anticuerpos procoagulantes
US12304928B2 (en) 2018-05-18 2025-05-20 Cz Biohub Sf, Llc Epitope restriction for antibody selection
US11220554B2 (en) 2018-09-07 2022-01-11 Novo Nordisk A/S Procoagulant antibodies
CN111378026A (zh) * 2018-12-27 2020-07-07 天津键凯科技有限公司 一种制备结合位点可控的peg化生物分子的方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4686112A (en) * 1983-01-13 1987-08-11 Rca Corporation Deposition of silicon dioxide
US4757006A (en) * 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4970300A (en) * 1985-02-01 1990-11-13 New York University Modified factor VIII
ATE72838T1 (de) 1985-04-12 1992-03-15 Genetics Inst Neue prokoagulierungsproteine.
US5250421A (en) * 1986-01-03 1993-10-05 Genetics Institute, Inc. Method for producing factor VIII:C-type proteins
US5198349A (en) * 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
JPH0387173A (ja) 1987-09-10 1991-04-11 Teijin Ltd ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
DE3889853D1 (de) 1987-11-05 1994-07-07 Hybritech Inc Polysaccharidmodifizierte Immunglobuline mit reduziertem immunogenem Potential oder verbesserter Pharmakokinetik.
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5633425A (en) * 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) * 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) * 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69133476T2 (de) * 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
GB9022543D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Antibody production
US6037452A (en) * 1992-04-10 2000-03-14 Alpha Therapeutic Corporation Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
ES2154650T3 (es) * 1992-10-02 2001-04-16 Genetics Inst Composicion que comprende una formulacion con factor de coagulacion viii, procedimiento para su preparacion y uso de un tensioactivo como estabilizador.
GB9225448D0 (en) 1992-12-04 1993-01-27 Erba Carlo Spa Improved synthesis of polymer bioactive conjugates
AU6029594A (en) 1993-01-15 1994-08-15 Enzon, Inc. Factor viii - polymeric conjugates
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US6548644B1 (en) 1997-03-10 2003-04-15 Immunex Corporation Site protected protein modification
US5830698A (en) * 1997-03-14 1998-11-03 Idec Pharmaceuticals Corporation Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
WO1999003496A1 (en) * 1997-07-21 1999-01-28 The University Of North Carolina At Chapel Hill Factor ix antihemophilic factor with increased clotting activity
US7074878B1 (en) 1999-12-10 2006-07-11 Harris J Milton Hydrolytically degradable polymers and hydrogels made therefrom
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
MXPA04004336A (es) * 2001-11-07 2005-05-16 Nektar Therapeutics Al Corp Polimeros ramificados y sus conjugados.
LT1596887T (lt) * 2003-02-26 2022-04-25 Nektar Therapeutics Polimero-faktoriaus viii fragmento konjugatai
AU2004228793B2 (en) 2003-04-08 2009-10-08 Yeda Research And Development Co. Ltd. Reversible pegylated drugs
KR101113726B1 (ko) * 2003-08-12 2012-02-27 리폭센 테크놀로지즈 리미티드 단백질 유도 및 컨쥬게이션용 시알산 유도체
ES2593318T3 (es) * 2004-08-12 2016-12-07 Lipoxen Technologies Limited Derivados de ácido siálico
BRPI0611872B8 (pt) 2005-06-16 2021-05-25 Nektar Therapeutics reagente polimérico, conjugado, método para preparação de um conjugado e composição farmacêutica
NZ572050A (en) * 2006-03-31 2011-09-30 Baxter Int Factor VIII conjugated to polyethylene glycol

Also Published As

Publication number Publication date
EP2349341A2 (en) 2011-08-03
US20100093934A1 (en) 2010-04-15
AU2009303368A1 (en) 2010-04-22
JP2012505901A (ja) 2012-03-08
CA2738064A1 (en) 2010-04-22
WO2010045321A2 (en) 2010-04-22
ES2441941T3 (es) 2014-02-07
CA2738064C (en) 2013-03-19
JP4966434B2 (ja) 2012-07-04
US8143347B2 (en) 2012-03-27
AU2009303368B2 (en) 2012-04-05
EP2349341B1 (en) 2013-10-09
DK2349341T3 (da) 2014-01-06
WO2010045321A3 (en) 2010-09-10

Similar Documents

Publication Publication Date Title
PL2349341T3 (pl) Pegylacja rekombinowanych czynników krzepnięcia krwi w obecności przeciwciał zwierzęcych
IL243784A0 (en) Human cgrp receptor binding proteins
IL232009A (en) Protein isolate heterodimer alpha 4 in cell 7 specific antigen-binding and various aspects thereof
SG10201500328QA (en) Human c-fms antigen binding proteins
IL223989B (en) Albumin binding polypeptide, fusion protein or conjugate comprising said polypeptide, polynucleotide encoding said albumin binding polypeptide and various aspects related thereto
IL222961B (en) Dna-binding proteins and uses thereof
SG10201801945TA (en) Specific binding proteins and uses thereof
EP2121057A4 (en) POLYMERIZATION WITH PRECIPITATION OF PROTEINS FOR ELUTION IN A PHYSIOLOGICAL SOLUTION
BR112012004546A2 (pt) "terapêutica por proteínas ligantes dll4-ligantes"
IL212856A0 (en) Human antibodies against human tissue factor
IL210283A0 (en) Prostaglandin e2 binding proteins and uses thereof
PL2459224T3 (pl) Koniugaty białka związanego z krzepnięciem krwi
IL236237A (en) Tmem154 antibodies and their segments and uses
GB0807018D0 (en) Antibodies and treatment
ZA200901680B (en) Recombinant human interferon-like proteins
IL209455A0 (en) Methods of treatment utilizing binding proteins of the interleukin-21 receptor
ZA201100019B (en) Variant hhip1 protein and methods and uses thereof
IL205577A0 (en) Anti-factor b antibodies and their uses
GB0809279D0 (en) Histamine binding protein
GB0922384D0 (en) 68GA-labled human serum albumin
SI2459224T1 (sl) Konjugati krvnega koagulacijskega proteina
GB0715325D0 (en) Fertilisation protein
GB0904491D0 (en) Blood coagulation factors
GB0914470D0 (en) Blood coagulation factors
SG10202006468XA (en) Human antibodies against human tissue factor